Filter posts

Harvard Launches New Campaign to End Insurance Discrimination

Earlier this year, BIO launched our Value Campaign. One of the main goals of this …

Correcting the Record On Politico’s Misinformed Article

Politico recently explored the relationship between the biopharmaceutical industry and the Affordable Care Act (ACA). …

BIO Urges States to Use CMS Grants to Combat Discrimination by Health Plans

On June 15, the Centers for Medicare and Medicaid Services (CMS) announced $22 million in …

NYTimes Reports Insurers are Struggling, Their Own Data Says Otherwise

The New York Times’ Reed Abelson yesterday reported on the plight of insurers who are …

FasterCures Webinar: Value and Coverage

Today, FasterCures hosted a webinar to discuss how reimbursement decisions impact innovations needed to improve health. The …

Business Roundtable: The Reimbursement Landscape under ACA

As the Affordable Care Act is implemented, reimbursement for life-saving and life-enhancing drugs is one …

Cancer Insurance Checklist: Guía de Cobertura Médica para Personas con Cáncer

As the world marks World Cancer Day and the U.S. continues to implement the Affordable …

The Affordable Care Act is Here to Stay

The Patient Protection and Affordable Care Act (ACA) of 2010 includes provisions that could lead …

Show Me the Money: Reimbursement in an ACA World

A panel at the BIO CEO & Investor Conference focused on reimbursement discussed value from a …

Biosimilars Ahead, Proceed with Caution

By Richard M. Dolinar, M.D., Chairman, Alliance for Safe Biologic Medicines In today’s budget-constrained world, …